18 Oct 2017 - 2:05pm

Call us: +44 (0) 207 754 0050

Press Releases in Pharmaceuticals

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US

[PRESSWIRE] TAIPEI, Taiwan and CINCINNATI, Aug. 28, 2017 -- Lumosa Therapeutics Co., Ltd. ("Lumosa"), a Taipei-based biopharmaceutical company developing innovative therapies focused on the treatment of neurological and inflammatory disease, announced today the FDA has confirmed the 505(b)(2) regulatory pathway is appropriate for the submission of the NDA of LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US. 

Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024

[PRESSWIRE] DUBLIN, Aug. 18, 2017 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an offering by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), of $500 million aggregate principal amount of exchangeable senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). 

Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1%

[PRESSWIRE] DUBLIN, May 23, 2017 -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced that Emmy®and Tony® award-winning actress and singer, Kristin Chenoweth will kick off the "Less Red, More You" campaign today at an exclusive event in New York City.

World’s first combination of CurQfen® and Turmacin® for the most fast acting, long lasting superior Curcumin supplement on the market

[PRESSWIRE] Calgary, Alberta, Canada - 27 March, 2017 -- Developed by AOR, Curcumin Ultra combines superior free-form curcumin (CurQfen®) with water-soluble turmeric polysaccharides (Turmacin®) for a long lasting synergistic effect for inflammation and pain relief.

Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

[PRESSWIRE] SYDNEY, March 6, 2017 --Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) is pleased to announce that it has been awarded a grant of up to A$3m over three years under the Cooperative Research Centre Project (CRC-P) scheme managed by the Australian Department of Industry Innovation and Science (DIIS).


Subscribe to Press Releases in Pharmaceuticals